ArticleCureus2025
Safety Profile and Bleeding Complications of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Non-ST-elevation acute coronary syndrome (NSTE-ACS) remains a major contributor to morbidity and mortality worldwide. Optimal anticoagulation is critical for preventing complications, but the choice between fondaparinux and enoxaparin remains debated, particularly regarding bleeding and ischemic outcomes. The objective of this study was to compare the safety profile, bleeding complications, ischemic outcomes, mortality, and composite adverse events between fondaparinux and enoxaparin in NSTE-ACS patients in Bangladesh. Methods This prospective observational study enrolled 177 NSTE-ACS patients from Noakhali Medical College and Hospital, Bangladesh, between January and December 2022. Patients received either fondaparinux (n=87) or enoxaparin (n=90). Bleeding and ischemic events, mortality, and composite outcomes were assessed at baseline, 3-month, and 6-month follow-ups. Multivariable logistic regression was performed to evaluate predictors of composite outcomes. Results Total bleeding incidence was significantly lower in fondaparinux-treated patients (6.90% vs. 23.33%, p=0.002), notably during index hospitalization (4.60% vs. 17.78%, p=0.006). Fondaparinux significantly reduced myocardial infarction (3.45% vs. 14.44%, p=0.016), recurrent ischemia (11.49% vs. 24.44%, p=0.025), and hospitalization due to heart failure (4.60% vs. 14.44%, p=0.026). Mortality was lower with fondaparinux but not statistically significant (13.79% vs. 25.56%, p=0.050). The composite endpoint of mortality and ischemic events was significantly lower in fondaparinux-treated patients (20.69% vs. 40.00%, p=0.005). Multivariable analysis revealed fondaparinux as an independent protective factor against composite outcomes (OR=0.336, 95% CI: 0.166-0.683, p=0.003), with no significant predictive value found for age, sex, hypertension, diabetes, smoking, or time to intervention. Conclusions Fondaparinux demonstrates superior safety and effectiveness over enoxaparin in reducing bleeding complications and ischemic events among NSTE-ACS patients. These findings support its preferential use in resource-constrained clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.